This study aims to identify potential DYRK1A inhibitors from a curated database and utilize a QSAR model to predict the bioactivity of drug compounds in inhibiting the enzyme involved in tau protein oligomerization, a key process in AD pathology. 192...
BACKGROUND: Automated speech and language analysis (ASLA) is gaining momentum as a noninvasive, affordable, and scalable approach for the early detection of Alzheimer disease (AD). Nevertheless, the literature presents 2 notable limitations. First, m...
Alzheimer's disease (AD) is a progressive neurological disorder that causes brain cell degeneration and leads to dementia. Early and accurate detection of AD is crucial, as it allows timely treatment before the brain suffers permanent damage. In rece...
The aim of this study is to build and validate a model based on structural magnetic resonance imaging (sMRI) to predict the progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD). A total of 343 patients with MCI were selected fro...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the primary cause of dementia, responsible for 60-70% of global cases. It severely affects memory, cognitive function, and daily independence, placing a substantial emotional an...
BACKGROUND: Neuroimaging is crucial in the diagnosis of Alzheimer disease (AD). In recent years, artificial intelligence (AI)-based neuroimaging technology has rapidly developed, providing new methods for accurate diagnosis of AD, but its performance...
Early diagnosis of Alzheimer's disease (AD) requires blood biomarker tests sensitive to femtogram/mL concentrations. Graphene field-effect transistors (GFETs) are promising for this application, but suffer from device-to-device variability and requir...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the gradual decline in cognitive functions, particularly memory and reasoning. Early detection, especially during cognitive impairment (MCI) stage, is crucial for t...
BACKGROUND: Amyloid PET/CT is essential for quantifying amyloid-beta (Aβ) deposition in Alzheimer's disease (AD), with the Centiloid (CL) scale standardizing measurements across imaging centers. However, MRI-based CL pipelines face challenges: high c...
INTRODUCTION: Quantification of amyloid plaques (A), neurofibrillary tangles (T), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing t...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.